Hoyoung Maeng

Hoyoung M. Maeng, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Vaccine Branch


Dr. Maeng’s research focuses on harnessing the immune system to prevent and treat cancer. She believes that the essence of the NIH is "bench-to-bedside and back" exemplified by the vaccines that were invented by the researchers at the NIH and brought to clinical trials at the NIH Clinical Center. She leads the clinical trials team at the Vaccine Branch and is deeply involved in translating the preclinical findings into first-in-human clinical trials using cancer vaccines and other immune-modulatory agents.

Areas of Expertise

Cancer Vaccines
Cancer Immunotherapy
Early Clinical Trials
Immune Escape Of Cancer
Lynch Syndrome

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Key Publications

Cancer vaccines: translation from mice to human clinical trials

Maeng H, Terabe M, Berzofsky JA
Current Opnion in Immunology. 51: 111-122, 2018. [ Journal Article ]

Phase I clinical trial of an autologous dendritic cell vaccine against HER2 as a single agent immunotherapy shows safety and preliminary clinical benefit.

Maeng H, Moore BM, Bagheri H, Steinberg SM, Inglefield J, Dunham K, Wei WZ, Morris JC, Terabe M, England LC, Roberson B, Pack S, Miettinen MM, Barr FG, Panch S, Stroncek DF, Wood LV, and Berzofsky JA.
Frontiers Oncology. 11: 4979, 2021.
Full-Text Article
[ Journal Article ]

Cancer Vaccines-Translational Strategies.

Maeng HM, Berzofsky JA
Wehling - Principles of Translational Science Medicine 3e. [ Book Chapter ]

Cancer Vaccines

Berzofsky JA, Olkhanud PB, Maeng HM
Plotkin’s Vaccines. 8e. [ Book Chapter ]

Strategies for developing and optimizing cancer vaccines.

Maeng HM, Berzofsky JA
F1000 Research. 8: 2019. [ Journal Article ]


Data Manager (Contr.)
Giselle Martinez
Research Nurse
Marissa Mallek